News & Conferences

VaxForm Signs Cooperative R&D Agreement with USAMRIID

Oct 4, 2010 12:00 am

VaxForm has recently signed a Cooperative Research and Development Agreement to perform pre-formulation development, formulation development, non-clinical safety studies, stability studies, with the intent to prepare cGMP material leading to evaluation of a vaccine against Streptococcus Pyogenes sepsis and toxic shock.

Streptococcus pyogenes is a gram-positive bacterium which causes multiple diseases in humans.  Worldwide an estimated 500,000 people die annually from S.pyogenes infection. An additional 600 million cases of pharyngitis occur each year.  The annual cost to the health system in the US alone is estimated at $220 - 540 million per year to manage pharyngitis in children. An effective vaccine would allow for millions of dollars in medical cost savings by reducing the rate of disease in the population.  In an effort to prevent disease resulting from S.pyogenes infections a novel vaccine based on a recombinant protein fusion between streptococcal pyrogenic exotoxin B (SpeB), a cysteinyl protease, and streptococcal pyrogenic exotoxin A (SpeA), a superantigen, is in development. Because of the potential for broad protection against multiple strains and initial pre-clinical success the fusion protein is continuing in developing an optimal formulation. Treatment efficacy will be characterized using in vitro and in vivo methods. 

The vaccine being developed in the proposed CRADA will prevent diseases such as pharyngitis, impetigo, necrotizing fasciitis, streptococcal toxic shock syndrome and rheumatic heart disease caused by infection with the bacterium.

About VaxForm 

VaxForm, is a Limited Liability Company, based in Pennsylvania, performing consulting business in vaccine formulation development. VaxForm can provide the expertise required to efficiently move your product through discovery, pre-formulation characterization, formulation development and into clinical trials. VaxForm tailor each project to your needs and put together a solution to respect the environment and strategy of your business, and reach an effective solution to achieve your objectives to responds to the spectrum of global health needs.